Organogenesis Holdings Inc
NASDAQ:ORGO

  • LAST PRICE
    3.9600
  • TODAY'S CHANGE (%)
    -0.0800 (-1.9802%)
  • Bid / Lots
    3.9500/ 4
  • Ask / Lots
    3.9600/ 8
  • Open / Previous Close
    4.0000 / 4.0400
  • Day Range
    3.9550
    4.0150
  • 52 Week Range
    2.1650
    4.7050
  • Volume
    25,581

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 22, 2024

  • Nov 15, 2024

      Show headlines and story abstract

    • 9:25AM ET on Friday Nov 15, 2024 by Dow Jones
      Companies Mentioned: ORGO

      Organogenesis Commends Final LCDs

      Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination

      CANTON, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, commends today's decision by the U.S. Centers for Medicare & Medicaid Services (CMS) on local coverage determination (LCD) based on peer-reviewed and evidence-based data of clinical efficacy. The LCD covers skin substitute grafts/cellular and tissue-based products (CTP) for the treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU) in the Medicare population and is now set to become effective on February 12, 2025.

    • 9:25AM ET on Friday Nov 15, 2024 by Dow Jones
      Companies Mentioned: ORGO

      Organogenesis Commends Final LCDs

      Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination

      CANTON, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, commends today's decision by the U.S. Centers for Medicare & Medicaid Services (CMS) on local coverage determination (LCD) based on peer-reviewed and evidence-based data of clinical efficacy. The LCD covers skin substitute grafts/cellular and tissue-based products (CTP) for the treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU) in the Medicare population and is now set to become effective on February 12, 2025.

  • Nov 12, 2024

Peers Headlines